Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1989 1
1990 2
1991 1
1992 1
1993 1
1995 3
1997 3
1998 2
1999 1
2000 4
2001 1
2006 2
2007 2
2010 1
2011 11
2012 11
2013 1
2014 1
2015 2
2016 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year
Filters applied: . Clear all
Page 1
Agonist-stimulated [35S]GTPγS binding.
Raddatz R, Alper RH. Raddatz R, et al. Curr Protoc Pharmacol. 2007 Mar;Chapter 2:Unit2.6. doi: 10.1002/0471141755.ph0206s36. Curr Protoc Pharmacol. 2007. PMID: 21948168 No abstract available.
Receptors as drug targets.
Williams M, Raddatz R. Williams M, et al. Among authors: raddatz r. Curr Protoc Pharmacol. 2006 Apr;Chapter 1:Unit 1.1. doi: 10.1002/0471141755.ph0101s32. Curr Protoc Pharmacol. 2006. PMID: 22294163
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
Hudkins RL, Raddatz R, Tao M, Mathiasen JR, Aimone LD, Becknell NC, Prouty CP, Knutsen LJ, Yazdanian M, Moachon G, Ator MA, Mallamo JP, Marino MJ, Bacon ER, Williams M. Hudkins RL, et al. Among authors: raddatz r. J Med Chem. 2011 Jul 14;54(13):4781-92. doi: 10.1021/jm200401v. Epub 2011 Jun 2. J Med Chem. 2011. PMID: 21634396
Practical aspects of radioligand binding.
McKinney M, Raddatz R. McKinney M, et al. Among authors: raddatz r. Curr Protoc Pharmacol. 2006 Jul;Chapter 1:Unit1.3. doi: 10.1002/0471141755.ph0103s33. Curr Protoc Pharmacol. 2006. PMID: 22294165
47 results